Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples